{"id":817477,"date":"2025-02-25T08:11:09","date_gmt":"2025-02-25T13:11:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/"},"modified":"2025-02-25T08:11:09","modified_gmt":"2025-02-25T13:11:09","slug":"merus-to-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/","title":{"rendered":"Merus to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb.  25, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LpUnk0KqzccAwpdKYx_e5ZZVinUWyXO9rsyrI3GwhDRZA9zhIgWhV65fIjNLtny1BpZRbzss6qOtlJ6mnJCnTg==\" rel=\"nofollow\" target=\"_blank\"><u>Merus N.V.<\/u><\/a>\u00a0(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics<sup>\u00ae<\/sup>, Triclonics<sup>\u00ae<\/sup> and ADClonics<sup>\u00ae<\/sup>), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET<\/li>\n<\/ul>\n<p>The webcasts of the presentations will be contemporaneously available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0-1E9UKM0ZkPVPSeyIyZnzSFemaPl4ZW6SmN9Ams9ZCf9NevS5X5sTOKlykVnfzFuzllss18es58N6YMwVFZRfz7e2AImwsPRsXcDOaOjnM=\" rel=\"nofollow\" target=\"_blank\"><u>Investors page<\/u><\/a> of the Company&#8217;s website. The archived presentations will also be available there for a limited time after the event.<\/p>\n<p>\n        <strong><br \/>\n          <strong>About Merus<\/strong><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LpUnk0KqzccAwpdKYx_e5QRuC7dDkYKa4GvykyVjnJG1-EpZ99VYQueyb2ZZ6hWzcwW-L819fUi41uloAu_kpQ==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>Merus<\/u><br \/>\n        <\/a> is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QX-agK3__CAGxMYvYQ8GoeojWycZqqSMxxUB-GG6GN44-Uiliz_cPmd9acAGdbJdPDYoUwGLu8slyVbGa_YXKEsbtUhqhXKmBDdcSrXjDj08dyRaLnb8MDWib19EO7f5\" rel=\"nofollow\" target=\"_blank\"><u>Multiclonics<\/u><sup>\u00ae<\/sup><\/a>. Multiclonics<sup>\u00ae<\/sup> are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LpUnk0KqzccAwpdKYx_e5bAfgq5OLO3x0_UsY9vItISvGuRf1udewG7zCzsD0L3LiRd73GdJb9n-sagio3b_qw==\" rel=\"nofollow\" target=\"_blank\"><u>Merus\u2019 website<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qTRTblZHYR9yMsKUgRwnrI6iRe78fa801EYpDRPSB1Vp0hqAqOsLEbR4ED2KDSSZbrQeWC-JW2d3Ml3Gd7RHTCIOZbC0eXR4UIbHF4Snkec=\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p>Multiclonics<sup>\u00ae<\/sup>, Biclonics<sup>\u00ae<\/sup>, Triclonics<sup>\u00ae<\/sup> and ADClonics<sup>\u00ae<\/sup> are registered trademarks of Merus N.V.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjRjNmZiMGEtMDFkMS00OWE4LThkOWQtY2MzNTUzNmM0YmJkLTEwMzE4NTk=\/tiny\/Merus-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor and Media Inquiries:\r\nSherri Spear\r\nMerus N.V.\r\nSVP Investor Relations and Strategic Communications\r\n617-821-3246\r\ns.spear@merus.nl\r\n\r\nKathleen Farren\r\nMerus N.V.\r\nAssoc. Director IR\/Corp Comms\r\n617-230-4165\r\nk.farren@merus.nl<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Merus N.V.\u00a0(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics\u00ae, Triclonics\u00ae and ADClonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company&#8217;s website. The archived presentations will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Merus to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817477","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merus to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merus to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Merus N.V.\u00a0(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics\u00ae, Triclonics\u00ae and ADClonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company&#8217;s website. The archived presentations will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length &hellip; Continue reading &quot;Merus to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T13:11:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Merus to Present at Upcoming Investor Conferences\",\"datePublished\":\"2025-02-25T13:11:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/\"},\"wordCount\":192,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/\",\"name\":\"Merus to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=\",\"datePublished\":\"2025-02-25T13:11:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merus to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merus to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Merus to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) &#8212; Merus N.V.\u00a0(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics\u00ae, Triclonics\u00ae and ADClonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company&#8217;s website. The archived presentations will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length &hellip; Continue reading \"Merus to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-25T13:11:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Merus to Present at Upcoming Investor Conferences","datePublished":"2025-02-25T13:11:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/"},"wordCount":192,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/","name":"Merus to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=","datePublished":"2025-02-25T13:11:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzc2MiM2Nzc2MDgxIzIwMjAyODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Merus to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817477"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817477\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}